DIURIZONE POWDER
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
07-10-2015
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
DEXAMETHASONE, HYDROCHLOROTHIAZIDE
Available from:
Vetoquinol Ireland Limited
ATC code:
QC03AX01
INN (International Name):
DEXAMETHASONE, HYDROCHLOROTHIAZIDE
Dosage:
0.025/7.5
Pharmaceutical form:
Oral Powder
Prescription type:
POM
Therapeutic group:
Bovine, Equine Non Food
Therapeutic area:
Hydrochlorothiazide, combinations
Therapeutic indications:
Cardiovascular
Authorization status:
Authorised
Authorization date:
1989-10-11
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Diurizone Powder
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Oral powder.
A fine, free-flowing powder.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle
Horses declared as not being intended for slaughter for human consumption.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
_Cattle:_
Congestion and oedema of the udder
Persistent oedema during lactation
Pulmonary congestion and oedema
Oedema of surgical wounds
Oedema of allergic conditions
_Horses:_
Generalised congestion and oedema
Oedema of sheath
Anasarca
Oedema in allergic conditions
4.3 CONTRAINDICATIONS
Do not use in pregnant animals. Do not use in animals with viral infections, during the viraemic phase. Do not use in
animals with diabetes mellitus, congestive heart failure, chronic nephritis, osteoporosis or glaucoma. Do not use in animals
with hepatic encephalopathy. Do not use in cases of severe hypokalemia. Do not use in animals with known
hypersensitivity to the active ingredients. Do not use in horses for the treatment of laminitis.
Active Substances
Hydrochlorothiazide 75.0 mg/g
Dexamethasone
0.25 mg/g
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 22/09/2015_
_CRN 7021886_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS
None.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
The association Hydrochlorothiazide and Dexamethasone acetate may induce hepatic encephalopathy.
Corticosteroids may d
Read the complete document
